Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

News Conference News EuroPCR 2018

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

May 25, 2018

“Transient” STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

News Conference News EuroPCR 2018

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

Michael O'Riordan

May 24, 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

News Conference News EuroPCR 2018

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

May 22, 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

News Conference News EuroPCR 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

May 17, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.